Hubei Shiluo Technology Co.,Ltd | Shiluo Technology (Yiwu) Co.,Ltd
Raw material supplier for Human nutrition, animal nutrition, cosmetic
Phone:
0086-27-83298801
Time: 2021-03-18 06:32:56
Author: Hubei Shiluo Technology Co., Ltd
Click:
Recently, Laojin Mill launched a replenishing coffee with three flavors: L-carnitine mocha coffee, black wolfberry blueberry, and jasmine lily. The new product is selected from Yunnan's high-quality small-grain coffee, which is combined with the Chinese food culture to bring a cup of "punk health coffee".
In addition, this product does not contain flavors, colors, preservatives, and does not contain non-dairy creamer. And choose the natural sugar substitute erythritol, the main product is low sugar, low fat and 0kcal. It dissolves quickly in 3 seconds, which is convenient and quick. The packaging adopts the national tide playing card design, and the independent bag is filled with nitrogen to lock the freshness. New product buy two get one free campaign price 105g*7 bags/118 yuan.
the benifit of L-carnitine
Our body produces L-carnitine from the essential amino acid lysine via a specific biosynthetic pathway. Healthy individuals, including strict vegetarians, generally synthesize enough L-carnitine to prevent deficiency. However, certain conditions like pregnancy may result in increased excretion of L-carnitine, potentially increasing the risk for deficiency. (More information)
Because of its role in the transport of long-chain fatty acids from the cytosol to the mitochondrial matrix, L-carnitine is critical for mitochondrial fatty acid β-oxidation. (More information)
L-Carnitine supplementation is indicated for the treatment of primary systemic carnitine deficiency, which is caused by mutations in the gene that codes for the carnitine transporter, OCTN2. (More information)
L-Carnitine is also approved for the treatment of carnitine deficiencies secondary to inherited diseases, such as propionyl-CoA carboxylase deficiency and medium chain acyl-CoA dehydrogenase deficiency, and in patients with end-stage renal disease undergoing hemodialysis. (More information)
Evidence from randomized controlled trials suggests that L-carnitine or acylcarnitine esters may be useful adjuncts to standard medical treatment in individuals with cardiovascular disease. (More information)
Routine administration of L-carnitine to people with end-stage renal disease undergoing hemodialysis is not recommended unless it is to treat carnitine deficiency.